Quad Technologies Collaborates with University of Massachusetts Medical School to Highlight Benefits of Novel Cell Separation Solution

WOBURN, Mass.–(BUSINESS WIRE)–The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery. Quad Technologies (“Quad”), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with the University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.

Read More…